Travere Therapeutics(US:TVTX) ZACKS·2026-02-19 23:10分组1 - Travere Therapeutics reported quarterly earnings of $0.03 per share, aligning with the Zacks Consensus Estimate, compared to a loss of $0.73 per share a year ago, representing an earnings surprise of +16.73% [1] - The company posted revenues of $129.69 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 8.97%, and this is an increase from year-ago revenues of $74.79 million [2] - Travere has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed, losing about 27.1% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.07 on $135 million in revenues, and for the current fiscal year, it is $0.62 on $673.01 million in revenues [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]